NOVEL MRI CONTRAST AGENT FOR MONITORING THERMAL ABLATION

用于监测热消融的新型 MRI 造影剂

基本信息

批准号：
7719659
负责人：
Nathan J. McDannold
金额：
$ 2.82万
依托单位：
BRIGHAM AND WOMEN'S HOSPITAL
依托单位国家：
美国
项目类别：
财政年份：
2008
资助国家：
美国
起止时间：
2008-08-01 至 2009-07-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7719659
关键词：
Ablation Animal Experiments Coagulation Process Complication Computer Retrieval of Information on Scientific Projects Database Contrast Media Disadvantaged Effectiveness Encapsulated Excision Exposure to Feedback Funding Grant Heating Histology Image Image Enhancement Institution Invasive Lead Length of Stay Liposomes Liver Liver neoplasms Magnetic Resonance Imaging Malignant Neoplasms Methods Minor Monitor National Cancer Institute Numbers Operative Surgical Procedures Patients Performance Perfusion Phase Transition Rate Research Research Personnel Resources Safety Signal Transduction Source Standards of Weights and Measures Survival Rate Technology Temperature Testing Thermal Ablation Therapy Thesauri Time Tissues Treatment Effectiveness United States National Institutes of Health Week bioimaging cancer thermotherapy improved in vivo laboratory rabbit mortality noninvasive diagnosis novel technology/technique development

项目摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Project Summary Surgical resection has been shown to be an effective treatment for secondary liver tumors, with five-year survival rates between 20-30%. Unfortunately, only select patients are candidates for resection, and it has a relatively high complication rate. About 35% of patients suffer minor complications, 15% have more serious complications, and the mortality rate is 2-5%. In addition, the average hospital stay is about two weeks, even without complications. Minimally invasive methods to thermally coagulate liver tumors have eliminated some of these disadvantages and have been shown to be an effective alternative treatment. The number of patients who receive such thermal ablation treatments is growing rapidly, and this technology is poised to enter widespread use. A way to substantially improve the safety and effectiveness of these treatments would be to have a method to easily and reliably quantify the tissue online that has reached a sufficient thermal exposure to induce thermal coagulation. Our hypothesis is that a novel magnetic resonance imaging (MRI) contrast agent that is activated at a threshold temperature level can be used to reliably successfully monitor thermal ablation of liver tumors. This agent consists of paramagnetic material encapsulated in a liposome shell. When encapsulated, the material has a minimal effect on the MR signal intensity. The liposome shell undergoes a phase transition at a temperature (Tc) that can be precisely chosen, and MR signal enhancement occurs which can be easily detected with standard imaging methods. With a Tc of 57¿C, which is the approximate threshold for thermal coagulation for heating of at least a few seconds, the signal intensity enhancement thus indicates the regions that are thermally ablated. Since perfusion is halted after thermal coagulation, any released paramagnetic agent will remain in the tissue for an extended period of time, clearly marking the ablation progression. Our preliminary tests of this agent in vivo have demonstrated its basic functionally. Here, we propose in vivo animal experiments to extensively characterize its performance and to test its effectiveness in monitoring thermal ablation of liver tumors. This research will lead to more effective and safer thermal ablation treatments in liver, and perhaps allow more difficult cases to be feasibly treated with thermal ablation methods, since it would provide straightforward and reliable online feedback of the treatment progression. Thesaurus Terms: contrast media, liver neoplasm, magnetic resonance imaging, neoplasm /cancer thermotherapy, technology /technique development image enhancement, liposome, noninvasive diagnosis bioimaging /biomedical imaging, histology, laboratory rabbit Project Start: 22-FEB-2005 Project End: 31-JAN-2008 ICD: NATIONAL CANCER INSTITUTE IRG: RTB

该副本是使用众多研究子项目之一由NIH/NCRR资助的中心赠款提供的资源。子弹和调查员（PI）可能已经从其他NIH来源获得了主要资金，因此可以在其他清晰的条目中代表。列出的机构是对于中心，这是调查员的机构。项目摘要手术切除已被证明是对继发性肝肿瘤的有效治疗方法，五年生存率在20-30％之间。不幸的是，只有精选的患者是切除术的候选者，并且并发症率相对较高。大约35％的患者患有轻微的并发症，15％的并发症更为严重，死亡率为2-5％。此外，即使没有并发症，平均住院时间约为两个星期。热凝结肝肿瘤的最小侵入性方法已经消除了其中一些灾难，并已被证明是一种有效的替代治疗方法。接受此类热消融治疗的患者人数正在迅速增长，该技术被毒死以进入宽度。实质上提高这些处理的安全性和有效性的一种方法是，有一种方法可以轻松，可靠地量化在线组织，该组织已达到足够的热暴露以诱导热凝结。我们的假设是，在阈值温度水平上激活的新型磁共振成像（MRI）对比剂可用于可靠地成功监测肝肿瘤的热消融。该试剂由封装在脂质体壳中的顺磁性材料组成。封装后，材料对MR信号强度的影响最小。脂质体外壳在可以精确选择的温度（TC）下经历相变，而MR信号增强发生，可以通过标准成像方法轻松检测到MR信号增强。 TC为57°C，这是至少几秒钟加热热凝结的近似阈值，因此信号强度增强表明了热消融的区域。由于热凝结后灌注会停止，因此任何释放的顺磁剂都会长时间保留在组织中，清楚地标志着消融进展。我们对体内试剂的初步测试已在功能上证明了其基本测试。在这里，我们提出体内动物实验，以广泛的表征其性能，并测试其在监测肝肿瘤热消融中的有效性。这项研究将导致肝脏中更有效，更安全的热消融治疗，并可能允许使用热消融方法对更困难的病例进行治疗，因为它将提供治疗进展的直接可靠的在线反馈。词库术语：对比培养基，肝脏肿瘤，磁共振成像，肿瘤 /癌症热疗，技术 /技术开发图像增强图像增强，脂质体，无创诊断生物成像 /生物医学成像，组织学，组织学，实验室兔子项目开始：2005年2月22日项目结束：2008年1月31日 ICD：国家癌症研究所 IRG：RTB